Scalper1 News
Biotech stocks fell hard Monday as troubles among the No. 1-rated group overshadowed a rally in commodities stocks. The Nasdaq Biotechnology Index lost 4.1%. Stocks retreating in above-average volume included Biogen (BIIB), Insys Therapeutics (INSY) and Celgene (CELG). Each of the stocks carries an IBD Composite Rating of 97 or better, putting the stocks in at least the top 3 percentile. The Composite Rating combines all five IBD Scalper1 News
Scalper1 News